NO20020763L - Vaksine - Google Patents

Vaksine

Info

Publication number
NO20020763L
NO20020763L NO20020763A NO20020763A NO20020763L NO 20020763 L NO20020763 L NO 20020763L NO 20020763 A NO20020763 A NO 20020763A NO 20020763 A NO20020763 A NO 20020763A NO 20020763 L NO20020763 L NO 20020763L
Authority
NO
Norway
Prior art keywords
vaccine
Prior art date
Application number
NO20020763A
Other languages
English (en)
Other versions
NO20020763D0 (no
NO328112B1 (no
Inventor
Brigitte Desiree Alberte Colau
Francoise Denamur
Isabelle Knott
Annick Poliszczak
Georges Thiry
Vincent Vande Velde
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO20020763D0 publication Critical patent/NO20020763D0/no
Publication of NO20020763L publication Critical patent/NO20020763L/no
Publication of NO328112B1 publication Critical patent/NO328112B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216Solid or semisolid forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12321Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12351Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO20020763A 1999-08-17 2002-02-15 Svekket human rotaviruspopulasjon, fremgangsmate for a fremstille denne, samt vaksinepreparat omfattende den svekkede rotaviruspopulasjon, fremgangsmate for a fremstille rotavirusvaksine og anvendelse av svekket humant rotavirus for fremstilling av vaksine NO328112B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine
PCT/EP2000/007965 WO2001012797A2 (en) 1999-08-17 2000-08-15 Method of separating rotavirus variants and live attenuated rotavirus vaccine

Publications (3)

Publication Number Publication Date
NO20020763D0 NO20020763D0 (no) 2002-02-15
NO20020763L true NO20020763L (no) 2002-04-16
NO328112B1 NO328112B1 (no) 2009-12-07

Family

ID=26315853

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20020763A NO328112B1 (no) 1999-08-17 2002-02-15 Svekket human rotaviruspopulasjon, fremgangsmate for a fremstille denne, samt vaksinepreparat omfattende den svekkede rotaviruspopulasjon, fremgangsmate for a fremstille rotavirusvaksine og anvendelse av svekket humant rotavirus for fremstilling av vaksine
NO2010011C NO2010011I2 (no) 1999-08-17 2010-05-19 Levende svekket humant rotavirus stamme Rix 4414 (Rotavirus vaksine)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2010011C NO2010011I2 (no) 1999-08-17 2010-05-19 Levende svekket humant rotavirus stamme Rix 4414 (Rotavirus vaksine)

Country Status (42)

Country Link
US (4) US7285280B1 (no)
EP (1) EP1212084B1 (no)
JP (3) JP2003507040A (no)
KR (1) KR100695599B1 (no)
CN (1) CN100379451C (no)
AP (1) AP1768A (no)
AR (1) AR029643A1 (no)
AT (1) ATE327765T1 (no)
AU (1) AU767885B2 (no)
BG (1) BG65314B1 (no)
BR (1) BRPI0013357B8 (no)
CA (1) CA2379196C (no)
CO (1) CO5580165A1 (no)
CY (2) CY1106103T1 (no)
CZ (1) CZ302173B6 (no)
DE (2) DE122006000026I1 (no)
DK (1) DK1212084T3 (no)
DZ (1) DZ3219A1 (no)
EA (1) EA005952B1 (no)
ES (1) ES2260046T3 (no)
FR (1) FR06C0018I2 (no)
HK (1) HK1046860B (no)
HU (2) HU228975B1 (no)
IL (3) IL147926A0 (no)
LU (1) LU91251I2 (no)
MA (1) MA25489A1 (no)
MX (1) MXPA02001648A (no)
MY (1) MY133158A (no)
NL (1) NL300233I2 (no)
NO (2) NO328112B1 (no)
NZ (1) NZ517131A (no)
OA (1) OA12312A (no)
PE (1) PE20010487A1 (no)
PL (1) PL205550B1 (no)
PT (1) PT1212084E (no)
SI (1) SI1212084T1 (no)
SK (1) SK287261B6 (no)
TR (1) TR200200420T2 (no)
TW (1) TWI283270B (no)
UA (1) UA77388C2 (no)
UY (1) UY26297A1 (no)
WO (1) WO2001012797A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228975B1 (en) * 1999-08-17 2013-07-29 Smithkline Beecham Biolog Vaccine
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
RU2368392C2 (ru) 2003-09-02 2009-09-27 ГлаксоСмитКлайн Байолоджикалз с.а. Применение аттенуированного ротавирусного штамма серотипа g1 в изготовлении композиции для индукции иммунного ответа на ротавирусную инфекцию
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AU2006281566B2 (en) * 2005-08-17 2011-09-01 Glaxosmithkline Biologicals S.A. Rotavirus vaccine inducing heterotypic cross protection
EP1969001A2 (en) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus and sapovirus antigens
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
EP2429577B1 (en) 2009-05-12 2019-01-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, New human rotavirus strains and vaccines
US9598676B2 (en) 2009-07-13 2017-03-21 Bharat Biotech International Limited Composition useful as rotavirus vaccine and a method therefor
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2013160913A1 (en) 2012-04-23 2013-10-31 Bharat Biotech International Limited Rotavirus vaccine compositions and process for preparing the same
AU2013308377B2 (en) * 2012-08-27 2019-06-06 Murdoch Childrens Research Institute Modified human rotaviruses and uses therefor
SI3299384T1 (sl) * 2015-05-21 2022-05-31 Xiamen University Skrajšan protein rotavirusa VP4 in njegova uporaba
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
RU2018126322A (ru) * 2015-12-18 2020-01-20 Мерк Шарп И Доум Корп. Термически стабильные ротавирусные вакцинные композиции и способы их применения
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
US4341763A (en) 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
US4624850A (en) 1984-02-09 1986-11-25 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
JP2753393B2 (ja) * 1990-11-16 1998-05-20 チルドレンズ ホスピタル メディカル センター ヒトロタウイルス,ワクチンおよび方法
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998013065A1 (en) * 1996-09-26 1998-04-02 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
HU228975B1 (en) * 1999-08-17 2013-07-29 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
SK287261B6 (sk) 2010-04-07
NO20020763D0 (no) 2002-02-15
NZ517131A (en) 2003-07-25
BRPI0013357B8 (pt) 2021-05-25
CO5580165A1 (es) 2005-11-30
US20080063662A1 (en) 2008-03-13
UY26297A1 (es) 2001-03-16
FR06C0018I2 (fr) 2007-04-27
ES2260046T3 (es) 2006-11-01
TR200200420T2 (tr) 2002-05-21
DE60028390D1 (de) 2006-07-06
NL300233I2 (nl) 2006-10-02
WO2001012797A3 (en) 2001-08-02
LU91251I2 (fr) 2006-08-14
PT1212084E (pt) 2006-07-31
OA12312A (en) 2006-05-12
UA77388C2 (uk) 2006-12-15
DZ3219A1 (fr) 2001-02-22
JP2007319164A (ja) 2007-12-13
US7285280B1 (en) 2007-10-23
US7790180B2 (en) 2010-09-07
MY133158A (en) 2007-10-31
LU91251I9 (no) 2018-12-31
TWI283270B (en) 2007-07-01
BRPI0013357B1 (pt) 2016-08-02
JP2011045374A (ja) 2011-03-10
BG106417A (en) 2003-04-30
CA2379196C (en) 2015-05-26
AP1768A (en) 2007-08-16
ATE327765T1 (de) 2006-06-15
MA25489A1 (fr) 2002-07-01
NO2010011I1 (no) 2010-06-07
US7790179B2 (en) 2010-09-07
AU767885B2 (en) 2003-11-27
EA200200142A1 (ru) 2002-08-29
CY1106103T1 (el) 2010-07-28
DE122006000026I1 (de) 2006-10-12
KR100695599B1 (ko) 2007-03-14
HK1046860B (zh) 2006-10-06
JP2003507040A (ja) 2003-02-25
AP2002002424A0 (en) 2002-03-31
BG65314B1 (bg) 2008-01-31
HU228975B1 (en) 2013-07-29
CY2006004I1 (el) 2009-11-04
PL205550B1 (pl) 2010-04-30
SI1212084T1 (sl) 2006-08-31
CY2006004I2 (el) 2009-11-04
CN1379683A (zh) 2002-11-13
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
IL147926A0 (en) 2002-08-14
PL354135A1 (en) 2003-12-29
AR029643A1 (es) 2003-07-10
AU6996100A (en) 2001-03-13
FR06C0018I1 (no) 2006-07-21
CN100379451C (zh) 2008-04-09
KR20020092344A (ko) 2002-12-11
IL188686A0 (en) 2008-04-13
US20080057082A1 (en) 2008-03-06
EP1212084A2 (en) 2002-06-12
BR0013357A (pt) 2002-04-30
HK1046860A1 (en) 2003-01-30
NO328112B1 (no) 2009-12-07
MXPA02001648A (es) 2002-08-06
NO2010011I2 (no) 2015-02-02
PE20010487A1 (es) 2001-06-23
HUS1300072I1 (hu) 2019-11-28
JP5474720B2 (ja) 2014-04-16
HUP0203335A1 (hu) 2003-02-28
NL300233I1 (nl) 2006-09-01
CA2379196A1 (en) 2001-02-22
HUP0203335A3 (en) 2004-07-28
DK1212084T3 (da) 2006-07-10
US20090130145A1 (en) 2009-05-21
SK2432002A3 (en) 2002-09-10
EP1212084B1 (en) 2006-05-31
CZ2002522A3 (cs) 2002-05-15
WO2001012797A2 (en) 2001-02-22
CZ302173B6 (cs) 2010-11-24
IL147926A (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20014322D0 (no) Vaksine
DE60045324D1 (de) Impfstoffzusammensetzung
NO20021433L (no) Vaksiner
NO20031483L (no) Vaksine
CY2011008I2 (el) Εμβολιο γριπης
ATA51899A (de) Handstempel
NO20024172D0 (no) Vaksine
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20006191D0 (no) Vaksine
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
NO20020763L (no) Vaksine
EE200200150A (et) Preparaat
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE50015451D1 (de) Spülwannensystem
NO20005599L (no) Vaksine
ATE269311T1 (de) Benzoylpyridazine
ATA121799A (de) Ausbeulgerät
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
AT500658A3 (de) Isolierplatte
ATA732000A (de) Kachelofen
NO20002213D0 (no) Babesia vaksine
FI3975U1 (fi) Ryömintäeristyssovitelma
FIU990234U0 (fi) Vuoka
ATA75399A (de) Kryoklemme

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ROTARIX; NAT. REG. NO/DATE: EU/1/05/330/001-004/N 20060308; FIRST REG. NO/DATE: EU/1/05/330/001-004 20060221

Spc suppl protection certif: 2010011

Filing date: 20100519

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ROTARIX; REG. NO/DATE: EU/1/05/330/001-004 20060308

Spc suppl protection certif: 2010011

Filing date: 20100519

Extension date: 20210221

MK1K Patent expired
SPCX Expiry of an spc

Free format text: PRODUCT NAME: LEVENDE, SVEKKET HUMANT ROTAVIRUS STAMME RIX 4414 (ROTAVIRUS VAKSINE)

Spc suppl protection certif: 2010011

Effective date: 20210302